Breaking: B. Riley FBR Keeps $8 Price Objective On Amyris (NASDAQ:AMRS) Shares, Keeps Their Original Buy Rating

Amyris, Inc. (NASDAQ:AMRS) Logo

Amyris (NASDAQ:AMRS) Rating Reaffirmed

B. Riley FBR now has a $8 PT on the $259.72 million market cap company or 97.29 % upside potential. In a note revealed on Wednesday morning, Amyris (NASDAQ:AMRS) shares have had their Buy Rating restate by research professionals at B. Riley FBR.

The stock decreased 31.27% or $1.845 during the last trading session, reaching $4.055. About 5.72M shares traded or 409.42% up from the average. Amyris, Inc. (NASDAQ:AMRS) has risen 148.90% since November 14, 2017 and is uptrending. It has outperformed by 133.28% the S&P500.

Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company has market cap of $259.72 million. The firm uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It currently has negative earnings. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

More notable recent Amyris, Inc. (NASDAQ:AMRS) news were published by: which released: “Amyris Reports Third Quarter 2018 Financial Results” on November 13, 2018, also with their article: “Pre-Open Movers 11/14: (CLD) (PETQ) (AMRN) Higher; (AMRS) (PCG) (MCD) Lower (more…)” published on November 14, 2018, published: “Amyris misses by $0.46, misses on revenue” on November 13, 2018. More interesting news about Amyris, Inc. (NASDAQ:AMRS) were released by: and their article: “Microcaps tops list of midday movers” published on November 14, 2018 as well as‘s news article titled: “10 Stocks Moving In Tuesday’s After-Hours Session” with publication date: November 13, 2018.

Amyris, Inc. (NASDAQ:AMRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.